Case Report: High-Level MET Amplification as a Resistance Mechanism of ROS1-Tyrosine Kinase Inhibitors in ROS1-Rearranged Non-Small Cell Lung Cancer

BackgroundAlthough C-ros oncogene 1 (ROS1) targeted therapies have demonstrated remarkable efficacy in ROS1-rearranged non-small cell lung cancer (NSCLC), patients inevitably develop resistance to ROS1-tyrosine kinase inhibitors (TKIs). Commonly acquired resistance mechanisms include a second mutati...

Full description

Bibliographic Details
Published in:	Frontiers in Oncology
Main Authors:	Jiangping Yang, Ping Zhou, Min Yu, Yan Zhang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-05-01
Subjects:	MET amplification ROS1 crizotinib resistance non-small cell lung cancer
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2021.645224/full

Similar Items

Efficacy and Tolerability of ALK/MET Combinations in Patients With ALK-Rearranged Lung Cancer With Acquired MET Amplification: A Retrospective Analysis
by: Ibiayi Dagogo-Jack, MD, et al.
Published: (2023-08-01)

Efficacy of Crizotinib After Entrectinib Resistance Due to MET Polysomy in ROS1-Rearranged NSCLC: A Case Report
by: Toshiaki Takakura, MD, et al.
Published: (2023-06-01)

MET kinase inhibitor reverses resistance to entrectinib induced by hepatocyte growth factor in tumors with NTRK1 or ROS1 rearrangements
by: Yohei Takumi, et al.
Published: (2023-03-01)

TARGETED THERAPY OF LUNG CANCER WITH THE ROS1 REARRANGEMENT
by: K. K. LAKTIONOV, et al.
Published: (2017-06-01)

Progress of c-MET Signaling Pathway and TKIs in Non-small Cell Lung Cancer
by: Xiaoqing YU, et al.
Published: (2017-04-01)

Efficacy and Clinical Outcomes of Crizotinib in Patients with ROS1-Rearranged NSCLC: A Multicenter Study
by: Alper Topal, et al.
Published: (2025-03-01)

Unusual Resistance Mechanisms in a Case of ROS1-Rearranged NSCLC: A Case Report
by: Ullas Batra, MD, et al.
Published: (2022-03-01)

Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
by: Wenxian Wang, et al.
Published: (2019-02-01)

MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC
by: Logan C. Tyler, et al.
Published: (2022-11-01)

Response to crizotinib in advanced intrahepatic cholangiocarcinoma with ZKSCAN1-MET fusion and MET amplification: case reports and literature review
by: Jian-Hui Wu, et al.
Published: (2025-06-01)

Clinical Efficacy of Crizotinib as the First-Line Therapy of Advanced Non-Small-Cell Lung Carcinoma with ROS-1 Rearrangement: A Systematic Review
by: Muhamad Rizqy Fadhillah, et al.
Published: (2023-06-01)

A Real‐World Study: Therapeutic Outcomes of ROS1‐Positive Advanced NSCLC
by: Hanqi Yuan, et al.
Published: (2025-05-01)

A novel co-existing ZCCHC8-ROS1 and de-novo MET amplification dual driver in advanced lung adenocarcinoma with a good response to crizotinib
by: You-cai Zhu, et al.
Published: (2018-12-01)

A case of ROS1‐rearranged lung adenocarcinoma exhibiting pleural effusion caused by crizotinib
by: Hiroaki Tachi, et al.
Published: (2020-07-01)

ROS1 in non-small-cell lung carcinoma: A narrative review
by: Shrinidhi Nathany, et al.
Published: (2022-01-01)

Response to gefitinib/crizotinib combination in a pulmonary sarcomatoid carcinoma patient harboring concurrent EGFR mutation and MET amplification
by: Xiaomeng Wang, et al.
Published: (2021-07-01)

Association of PD-L1 expression and clinical outcomes in ROS1 - rearranged advanced non-small cell lung cancer treated with crizotinib
by: Huixian Zhang, et al.
Published: (2024-05-01)

Correlating ROS1 Protein Expression With ROS1 Fusions, Amplifications, and Mutations
by: Richard S.P. Huang, MD, et al.
Published: (2021-02-01)

Crizotinib-Related Aseptic Abscesses in Lung Adenocarcinoma and <i>ROS1</i>-Gene Rearrangement: A Case Report
by: Thamires Oliveira-Silva, et al.
Published: (2025-01-01)

Association of anticoagulant use with clinical outcomes from crizotinib in ALK‐ and ROS1‐rearranged advanced non‐small cell lung cancers: A retrospective analysis of PROFILE 1001
by: Terry L. Ng, et al.
Published: (2022-12-01)

Gastric cancer patient with c-MET amplification treated with crizotinib after failed multi-line treatment: A case report and literature review
by: Guoxin Hou, et al.
Published: (2019-06-01)

Reactive Oxygen Species (ROS)-Sensitive Prodrugs of the Tyrosine Kinase Inhibitor Crizotinib
by: Bjoern Bielec, et al.
Published: (2020-03-01)

First‐line crizotinib versus platinum‐pemetrexed chemotherapy in patients with advanced ROS1‐rearranged non‐small‐cell lung cancer
by: Lan Shen, et al.
Published: (2020-05-01)

Crizotinib resistance conferred by BRAF V600E mutation in non–small cell lung cancer harboring an oncogenic ROS1 fusion
by: Shuang Ren, et al.
Published: (2021-01-01)

Long-term efficacy of crizotinib in a metastatic papillary renal carcinoma with MET amplification: a case report and literature review
by: Philippe Rochigneux, et al.
Published: (2018-11-01)

The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations
by: Balázs Jóri, et al.
Published: (2023-09-01)

Fatal interstitial lung disease associated with Crizotinib pathologically confirmed by percutaneous lung biopsy in a patient with ROS1-rearranged advanced non-small-cell lung cancer: a case report
by: Shibo Wu, et al.
Published: (2018-07-01)

Entrectinib Response to ROS1-Fusion-Positive Non-Small-Cell Lung Cancer That Progressed on Crizotinib with Leptomeningeal Metastasis: A Case Report
by: Hiromune Sawada, et al.
Published: (2023-12-01)

Case report: complete remission with crizotinib in ROS1 fusion-positive sinonasal mucosal melanoma
by: Jun Cao, et al.
Published: (2022-10-01)

Real-world studies of crizotinib in patients with ROS1-positive non-small-cell lung cancer: experience from China
by: Hua Zhong, et al.
Published: (2024-12-01)

Real-World Management and Outcomes of Crizotinib-Treated ROS1-Rearranged NSCLC: A Retrospective Canadian Cohort
by: Amanda J. W. Gibson, et al.
Published: (2022-03-01)

The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC
by: Tejas Patil, MD, et al.
Published: (2024-02-01)

Crizotinib Treatment for Lorlatinib-resistant MET-amplified EML4-ALK-fusion Positive Advanced Lung Adenocarcinoma: A Case Report
by: Xinyi WANG, et al.
Published: (2024-12-01)

Identification of ALK, ROS1, RET, MET Mutation in EGFR Wild-Type Non-Small Cell Lung Cancer Patients and Their Associations with Clinicopathological Factors
by: Long Quang Pham, et al.
Published: (2026-05-01)

Exceptional long term response to crizotinib in ROS 1‐postive advanced non small cell lung cancer
by: Anjali Murali, et al.
Published: (2024-09-01)

QSAR, molecular docking and ADMET properties in silico studies of novel 4,5,6,7-tetrahydrobenzo[D]-thiazol-2-Yl derivatives derived from dimedone as potent anti-tumor agents through inhibition of C-Met receptor tyrosine kinase
by: Ossama Daoui, et al.
Published: (2021-07-01)

Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC
by: Alexander Drilon, MD, et al.
Published: (2022-06-01)

Crizotinib vs platinum‐based chemotherapy as first‐line treatment for advanced non‐small cell lung cancer with different ROS1 fusion variants
by: Haiyan Xu, et al.
Published: (2020-05-01)

Advances in MET tyrosine kinase inhibitors in gastric cancer
by: Yifan Zhang, et al.
Published: (2024-06-01)

Remarkable response to crizotinib in a patient with advanced lung adenocarcinoma harboring the MPRIP-ROS1 fusion gene: A case report
by: Yasuyuki Kishikawa, et al.
Published: (2025-01-01)